Inivata Names Clive Morris New CEO
Executive Summary
Inivata's Chief Medical Officer Clive Morris will take over as CEO of the liquid biopsy company. Former CEO Michael Stocum departed earlier this year.
You may also be interested in...
Market Intel: Liquid Biopsy – Ready For Prime Time?
Liquid biopsy is a rapidly developing noninvasive technology for the early detection of cancer. Multiple companies have entered clinical testing, using mostly blood to detect circulating tumor cells and/or circulating tumor DNA. But urine and even cerebral spinal fluid are promising liquids too. Regardless of the fluid, testing costs a fraction of a traditional, invasive tissue biopsy and offers much quicker results.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.